A Phase 2 interventional study of Denosumab and Placebo in Dense Breasts, sponsored by Washington University School of Medicine. Active, not recruiting at 1 site in United States. Open to female participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by Washington University School of Medicine · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing denosumab in Breast Neoplasms — none open to participants now, 3 under way, 2 of them phase 3. Denosumab · Breast Neoplasms.
Among the 24 studies testing denosumab in Breast Neoplasms, this one is the 9th largest by enrollment, is the only one that started in 2019, is one of 9 in phase 2, and was the 23rd registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →None of the 24 studies testing denosumab in Breast Neoplasms is open now. The open studies under Breast Neoplasms, anywhere →
Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 40 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 210 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 53 across the 24 interventional studies. Of the 17 that completed or were terminated, 12 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 24 have an industry lead sponsor. The 10 most frequent:
Washington University School of Medicine is the lead sponsor of 1,806 studies on the registry; 271 are open to participants now.
Of its 329 completed or terminated interventional studies of FDA-regulated products, 216 (66%) have results posted.
80 studies in Breast Neoplasms by Washington University School of Medicine: 18 open now, 22 under way, none of them phase 3. Of 53 finished, 22 (42%) have results posted.
Among the 80 studies in Breast Neoplasms by Washington University School of Medicine, this one is the 8th largest by enrollment of the 74 interventional ones that give a count, is one of 3 that started in 2019, is one of 29 in phase 2, reaches primary completion later than 2 of the 21 other live ones, and was the 54th registered.
Washington University School of Medicine’s Breast Neoplasms studies by the year they started, since 2002.
1 of the studies testing denosumab in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04711109Phase 3Alliance for Clinical Trials in OncologyStudying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation | 2027-07 |
Add it to your calendar (.ics) → With an account.
Among the 24 studies testing denosumab in Breast Neoplasms, from their registry updates:
Among Washington University School of Medicine’s 80 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
Data supporting a role for RANKL signaling in mammographic density and breast cancer development has begun to emerge, but clinical trial data providing definitive evidence that would allow the adoption of RANKL inhibition in primary breast cancer prevention are not yet available. The hypothesis is that RANKL inhibition with denosumab will decrease mammographic density in high-risk premenopausal women with dense breasts. To address this, the investigators have developed this clinical trial to quantify the impact of RANKL inhibition on mammographic density in high-risk premenopausal women with dense breasts and to determine the effect of RANKL inhibition on markers of proliferation and biomarkers of breast cancer risk. Successful demonstration that RANKL inhibition reduces mammographic density could open up additional approaches to primary breast cancer prevention in high-risk premenopausal women, who do not have dominant genetic predisposition.
The criteria were revised on the registry on Oct 9, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
* Subcutaneous injection of denosumab at a dose of 60 mg at two time points: baseline and 6 months * Participants will also be instructed to take calcium and vitamin D supplements daily for 12 months between baseline examination and 12-month mammographic breast density examination. * Mammographic breast density will be assessed at three time points in all participants: baseline, 12 months, and 24 months. A 36-month optional assessment may also occur. * Biopsies and blood draws will occur for research purposes at baseline and 12 months.
Drug: Denosumab · Drug: Calcium · Drug: Vitamin D3 · Procedure: Core needle biopsy · Procedure: Blood draw
* Subcutaneous injection of the placebo at a dose of 60 mg at two time points: baseline and 6 months * Participants will also be instructed to take calcium and vitamin D supplements daily for 12 months between baseline examination and 12 month mammographic breast density examination * Mammographic breast density will be assessed at three time points in all participants: baseline, 12 months, and 24 months. A 36 month optional assessment may also occur. * Biopsies and blood draws will occur for research purposes at baseline and 12 months.
Drug: Placebo · Drug: Calcium · Drug: Vitamin D3 · Procedure: Core needle biopsy · Procedure: Blood draw
Denosumab is commercially available and will be provided at no cost to participants.
Also known as: Prolia
Placebo will be made available as 1 mL sterile, non-pyrogenic water solution in a single-use prefilled syringe.
-Participants will be instructed to take calcium (at least 500 mg) daily for 12 months between baseline examination and 12- month mammographic breast density examination.
Participants will be instructed to take vitamin D3 (at least 400 IU) supplements daily for 12 months between baseline examination and 12- month mammographic breast density examination.
Baseline and 12 months
Baseline and 12 months
Percent Change of Volumetric Percent Density Compared Between Baseline and 12 Months
-The investigators used volumetric percent density (VPD) as the primary mammographic breast density measure. The VPD percent change at 12 months from baseline was calculated as volumetric percent density at 12 months divided by baseline volumetric percent density minus 1\*100 (i.e., unit of percentage).
Time frame: At baseline and at 12 months
Percent Change of Volumetric Percent Density Compared Between Baseline and 24 Months
The VPD percent change at 12 months from baseline was calculated as volumetric percent density at 24 months divided by baseline volumetric percent density minus 1\*100 (i.e., unit of percentage).
Time frame: At baseline and 24 months
Percent Change of Volumetric Percent Density Compared Between Baseline and 36 Months
The VPD percent change at 12 months from baseline was calculated as volumetric percent density at 36 months divided by baseline volumetric percent density minus 1\*100 (i.e., unit of percentage).
Time frame: At baseline and 36 months
Changes in Expression of Genes Related to Progesterone in Breast Tissue Between the Two Arms
Time frame: Baseline and 12 months
Changes in Expression of Genes Related to Metabolic Markers in Breast Tissue Between the Two Arms
Time frame: Baseline and 12 months
Changes in Expression of Immune Related Genes in Breast Tissue Between the Two Arms
Time frame: Baseline and 12 months
Change in Breast Metabolome Between the Two Arms
Time frame: Baseline and 12 months
Changes in Expression of Markers of Breast Epithelial and Stromal Proliferation Between the Two Arms
Time frame: Baseline and 12 months
Changes in Expression of Inflammatory Genes in Breast Tissue Between the Two Arms
Time frame: Baseline and 12 months
Changes in Expression of Genes Related to RANK in Breast Tissue Between the Two Arms
Time frame: Baseline and 12 months
| Milestone | Denosumab | Placebo |
|---|---|---|
| Started | 105 | 105 |
| Completed | 101 | 102 |
| Not completed | 4 | 3 |
| Withdrew: Lost to follow-up | 4 | 2 |
| Withdrew: Participant withdrawal or refusal after beginning protocol therapy | 0 | 1 |
-The investigators used volumetric percent density (VPD) as the primary mammographic breast density measure. The VPD percent change at 12 months from baseline was calculated as volumetric percent density at 12 months divided by baseline volumetric percent density minus 1\*100 (i.e., unit of percentage).
| VPD percent change | Denosumab | Placebo |
|---|---|---|
| Percent Change of Volumetric Percent Density Compared Between Baseline and 12 Months | -1.13 ± 25.60 | 1.59 ± 25.95 |
The VPD percent change at 12 months from baseline was calculated as volumetric percent density at 24 months divided by baseline volumetric percent density minus 1\*100 (i.e., unit of percentage).
Results for this outcome have not been posted.
The VPD percent change at 12 months from baseline was calculated as volumetric percent density at 36 months divided by baseline volumetric percent density minus 1\*100 (i.e., unit of percentage).
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Collected over Adverse events were tracked for up to 24 months after baseline intervention.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Denosumab | 0/105 (0%) | 0/105 (0%) | 67/105 (63.8%) |
| Placebo | 0/105 (0%) | 0/105 (0%) | 64/105 (61%) |
| Event | Denosumab | Placebo |
|---|---|---|
| BruisingInjury, poisoning and procedural complications | 24/105 | 26/105 |
| Muscle CrampMusculoskeletal and connective tissue disorders | 10/105 | 8/105 |
| MyalgiaMusculoskeletal and connective tissue disorders | 8/105 | 4/105 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 7/105 | 4/105 |
| ParesthesiaNervous system disorders | 6/105 | 3/105 |
| ToothacheGastrointestinal disorders | 1/105 | 5/105 |
| Periodontal DiseaseGastrointestinal disorders | 3/105 | 4/105 |
| PruritusSkin and subcutaneous tissue disorders | 4/105 | 3/105 |
| NauseaGastrointestinal disorders | 2/105 | 3/105 |
| FatigueGeneral disorders | 3/105 | 2/105 |
| Age, Continuous(years) | Denosumab | Placebo | Total |
|---|---|---|---|
| Mean | 46 (40 to 55) | 46 (40 to 55) | 46 (40 to 55) |
| Sex: Female, Male(Participants) | Denosumab | Placebo | Total |
|---|---|---|---|
| Female | 105 | 105 | 210 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Denosumab | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 4 | 4 |
| Not Hispanic or Latino | 104 | 100 | 204 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Race (NIH/OMB)(Participants) | Denosumab | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 3 | 0 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 15 | 14 | 29 |
| White | 84 | 90 | 174 |
| More than one race | 2 | 0 | 2 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Region of Enrollment(participants) | Denosumab | Placebo | Total |
|---|---|---|---|
| United States | 105 | 105 | 210 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified participant data used in generating tables and figures in published manuscripts.
Time frame: IPD will be shared beginning 12 months, and ending 24 months following article publication.
Access criteria: IPD will be shared with investigators who propose a methodologically sound proposal. These proposals should have been reviewed and approved by independent review committees, including institutional review boards. Proposals should be directed to the Principal Investigator, who will review the request with other co-Investigators. Proposals may also be subject to further review by the Protocol Review Monitoring Committee and Institutional Review Board at Principal Investigator's institution. Requestors will need to sign an institutional data access agreement to gain access to the data.
Ran from Aug 2019 to primary completion in Sep 2025, 72 months.
Results were first posted in Oct 2026, 1 year after primary completion.
Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's 72 months is above that.
Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.
Completion moved once since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2027, on Oct 9, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Denosumab
Washington University School of Medicine →